Ocular Therapeutix

Valuation Analysis

About the Company

Ocular Therapeutix en bref

Ocular Therapeutix (OCUL) is currently trading at 7,08 € with a market capitalization of 1,6 Md €. The 52-week range spans from 5,40 € to 14,25 €; the current price is 50.3% below the yearly high. Year-over-year revenue growth stands at +0.8%.

💰 Dividende

Ocular Therapeutix currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

11 analystes évaluent Ocular Therapeutix (OCUL) au consensus : Achat Fort. L'objectif de cours moyen est de 23,49 €, soit un potentiel de +231.59% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 15,61 € à 29,48 €.

Ocular Therapeutix : la thèse d'investissement en détail

Ocular Therapeutix (OCUL) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Strong Buy with an average price target implying roughly 231.59% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Revenue growth has slowed to just 0.8%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Short interest sits at 14.58% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

À surveiller

• The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
• The analyst consensus price target implies 231.59% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (14.58%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Ocular Therapeutix?

Compare top-rated brokers — low fees, trusted providers, fully regulated.